22nd Century Group (Nasdaq: XXII) has acquired GVB Biopharma. Read the press release here

OVERVIEW


Latest Presentations

22nd Century Overview
View Presentation


22nd Century Overview of GVB Biopharma Acquisition
View Presentation


Our Hops Franchise and Market Overview
View Presentation

Latest News

22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position

View Press Release View All

22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs
View Press Release

22nd Century Group (XXII) Announces U.S. Distribution Partnerships with Core-Mark and Eby-Brown
View Press Release

FDA's Proposed Menthol Ban Advances to Final Rule Status, Greatly Benefits 22nd Century (XXII) by Affirming the Need for VLN(R) Menthol King as a Critical Off-Ramp for Adult Menthol Smokers
View Press Release

Investor Contact Information

Company

22nd Century Group, Inc.
500 Seneca Street, Suite 507
Buffalo, NY 14204
T: 716-270-1523
Contact Us

Investor Relations

Mei Kuo
22nd Century Group, Inc.
Director, Communications & Investor Relations
T: 716-300-1221
mkuo@xxiicentury.com

Darrow Associates Investor Relations
Matt Kreps
T: 214-597-8200
mkreps@darrowir.com

Transfer Agent

Continental Stock and Transfer Company
1 State Street, 30th Floor
New York, NY 10004
T: 212-509-4000
cstmail@continentalstock.com